The US Food and Drug Administration has approved VIZZ, a groundbreaking aceclidine-based eye drop that represents the first pharmacological treatment for presbyopia, marking a significant advancement in vision care for millions of Americans struggling with age-related near vision loss.

VIZZ (aceclidine ophthalmic solution 1.44%), developed by LENZ Therapeutics, offers a once-daily, non-surgical alternative to reading glasses for adults with presbyopia. The prescription eye drops work by contracting the iris sphincter muscle to create a "pinhole effect," achieving a pupil smaller than 2mm that extends depth of focus and improves near vision within 30 minutes